1. Impact of triple combination of gemcitabine‐based chemoirradiation with anti‐PD‐L1 in the KPC tumor allograft
Impact of triple combination of gemcitabine‐based chemoirradiation with anti‐PD‐L1 in the KPC tumor allograft AMice were treated with either gemcitabine (days 0, 3), anti‐PD‐L1 (days 4, 7, 10, and 13), 12 Gy (day 4) alone, or in combinations, as indicated (n = 8 mice per group). The average time (days) for tumors to reach a volume of 400 mm3 from day 0 is shown (means ± SD, n = 1, one‐way ANOVA, Bonferroni test). No weight loss was observed in the in vivo experiment.B, CRT plus anti‐PD‐L1 reverses T‐cell exhaustion (B) and increases CD8:Treg ratio (C). Bar graphs show quantitation of T‐cell activation markers and CD8:Treg ratio in tumor samples based on flow cytometry analysis, as indicated (n = 5 per group; means ± SD, n = 1, one‐way ANOVA, Bonferroni test).
Abul Azad et al. EMBO Mol Med. 2016;emmm
© as stated in the article, figure or figure legend